Peak Retirement Planning Inc. Raises Holdings in Hims & Hers Health, Inc. $HIMS

Peak Retirement Planning Inc. raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 64.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 82,567 shares of the company’s stock after acquiring an additional 32,471 shares during the quarter. Peak Retirement Planning Inc.’s holdings in Hims & Hers Health were worth $2,681,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Capital World Investors boosted its stake in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after purchasing an additional 223,892 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. State Street Corp boosted its stake in Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after purchasing an additional 132,384 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $27.51 on Wednesday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The stock’s fifty day moving average is $24.16 and its 200 day moving average is $27.29. The stock has a market cap of $6.37 billion, a P/E ratio of -305.68, a P/E/G ratio of 53.87 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the business posted $0.20 earnings per share. Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers completed its acquisition of Eucalyptus, giving it an immediate presence in Australia, Canada, Germany, and Japan and broadening its international growth opportunities. Article Title
• Positive Sentiment: The acquisition strengthens Hims & Hers’ position in clinically backed weight-management care and expands access to its digital health platform in major international markets. Article Title
• Neutral Sentiment: The company is also framing the deal as a step toward becoming the “world’s largest consumer health platform,” which may help sentiment but does not by itself guarantee near-term profitability. Article Title
• Negative Sentiment: Despite the expansion story, the stock remains highly valued and volatile, and recent investor focus on an “undervalued” thesis suggests the market may still be debating whether growth is enough to justify the price. Article Title

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Bank of America lowered their price target on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Tuesday, May 26th. Truist Financial increased their price target on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Needham & Company LLC increased their price target on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.70.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This trade represents a 3.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at approximately $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 212,807 shares of company stock worth $5,473,644 in the last quarter. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.